# Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/TECH/bio-techne-to-host-conference-call-on-february-4-2026-to-announce-second-quarter-fiscal-2026-financial-results
Ticker: TECH
Company: Bio-Techne
Source: Bio-Techne
Published: 2026-01-20 12:00 EST
Original Source URL: https://investors.bio-techne.com
## Summary

<div class="xn-content"> <p><span class="legendSpanClass">MINNEAPOLIS</span>, <span class="legendSpanClass">Jan. 20, 2026</span> /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its se

## Article Body
MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its second quarter fiscal 2026 financial results.

Access to the discussion may be obtained as follows:

Time:

8:00 a.m. CST

Date:

February 4, 2026

Dial-in:

1-800-579-2543 or 1-785-424-1789 (for international callers)

Conference ID:

TECHQ2

Webcast:

https://investors.bio-techne.com/ir-calendar

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11160826.

The replay will be available from 11:00 a.m. CST on Wednesday, February 4, 2026, until 11:00 p.m. CST on Wednesday, March 4, 2026.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.

Contact:

David Clair, Vice President, Investor Relations

david.clair@bio-techne.com

612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-february-4-2026-to-announce-second-quarter-fiscal-2026-financial-results-302663784.html

SOURCE Bio-Techne Corporation
## Recent Company News
- 2026-07-08 10:30 EST — [Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio](https://biopharmsignal.com/news/TECH/bio-techne-launches-expanded-r-d-systems-ai-engineered-designer-protein-portfoli-21b908e1) — Source: Bio-Techne
- 2026-06-25 10:10 EST — [Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets](https://biopharmsignal.com/news/TECH/merck-kgaa-darmstadt-germany-agrees-to-acquire-bio-techne-strengthening-leadersh-50e2ac1c) — Source: Bio-Techne
- 2026-06-04 10:30 EST — [Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization](https://biopharmsignal.com/news/TECH/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization) — Source: Bio-Techne
- 2026-05-06 10:30 EST — [Bio-Techne Declares Dividend](https://biopharmsignal.com/news/TECH/bio-techne-declares-dividend) — Source: Bio-Techne
- 2026-05-06 10:30 EST — [Bio-Techne Releases Third Quarter Fiscal 2026 Results](https://biopharmsignal.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2026-results) — Source: Bio-Techne
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
